# A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer

Source: https://onco.cc/trials/nct06194734/  
OnCo record `nct06194734` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing KC1036 in oesophageal cancer, now recruiting.

## Summary

A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Oesophageal Cancer is a phase 3 interventional study registered as NCT06194734, led by Beijing Konruns Pharmaceutical, and recruiting on the registry. Official title: A Randomised, Controlled, Open-label, Multicenter Phase III Study to Evaluate the Efficacy and Safety of KC1036 Versus Investigator's Choice of Chemotherapy as Third-line Therapy in Patients With Advanced Oesophageal Squamous Cell Carcinoma. Planned enrolment is 490 participants (estimated). The study started in 2024-02-05 and primary completion is expected in 2026-12-30. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT06194734
- Phase: 3
- Setting: A Randomized, Controlled, Open-label, Multicenter Phase III Study to Evaluate the Efficacy and Safety of KC1036 Versus Investigator's Choice of Chemotherapy as Third-line Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma
- Sponsor: Beijing Konruns Pharmaceutical
- Enrolled: 490

## Sources

- ClinicalTrials.gov NCT06194734: https://clinicaltrials.gov/study/NCT06194734

## Connected records

- cancers: [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Oesophageal squamous cell carcinoma](https://onco.cc/cancers/oesophageal-squamous-cell-carcinoma/)
- drugs: [KC1036](https://onco.cc/drugs/kc1036/)
- companies: [Beijing Konruns Pharmaceutical](https://onco.cc/companies/beijing-konruns-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct06194734.json